Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Pulmonary rheumatoid nodules (PRN) occur in 20%−25% of rheumatoid arthritis (RA) patients and can lead to complications.1 Disease-modifying antirheumatic drugs (leflunomide, methotrexate) and antitumour necrosis factor α (anti-TNFα) have been implicated in their development.2,–,4 The immunopathological characteristics of PRN are quite distinct from those of subcutaneous nodules with the presence of B lymphocytes expressing CD20 in the periphery.5 We therefore decided to assess the efficacy of rituximab (RTX) in patients with PRN using data from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry.6 Of the 10 patients studied, all but one (n 8) were positive for rheumatoid factors and anticitrullinated protein antibodies (anti-CCP). Five patients had a history of smoking: two were active smokers (n 2, 3), and three past smokers (n 5, 7, 9). All patients had previously received anti-TNF …
Competing interests None.
Patient consent Obtained.
Ethics approval Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé and Commission Nationalede l’Informatique et des Libertés.
Provenance and peer review Not commissioned; externally peer reviewed.